ft 21 oct 92 smithklin rise 8 quarter smithklin beecham anglo american healthcar group yesterday report third quarter profit 8 per cent pound 252m pound 272m particularli strong perform group pharmaceut oper offset fall stagnant profit anim health clinic laboratori consum brand busi group share close 15p 527p result achiev sale 9 per cent pound 1 28bn earn per share increas 13 per cent 6 8p 12 1 cent per equiti unit compani gener 50 per cent sale us suffer advers exchang rate compar rate sale increas 12 per cent trade profit 8 per cent pre tax profit 13 per cent pre tax profit first nine month pound 804m pound 735m sale pound 3 74bn pound 3 44bn pharmaceut oper post oper profit 11 per cent pound 173m sale increas 24 per cent pound 709m group new product perform well seroxat anti depress achiev 23 7 per cent market share uk mr hugh collum financ director said relafen smithklin beecham anti arthriti medicin third best sell non steroid anti inflammatori treatment us 10 per cent market valu kytril nausea prevent treatment cancer patient accept 90 per cent target clinic mr hugh collum said group also benefit except perform engerix b hepat b vaccin older product also perform well augmentin antibiot increas worldwid sale 41 per cent tagamet ulcer drug lost patent except us declin 4 per cent worldwid consum brand oper profit fell 5 per cent pound 68m sale 6 per cent pound 338m trade profit anim health divis declin pound 17m pound 16m group said market continu weak clinic laboratori oper profit static pound 18m sale 3 per cent pound 144m compani propos third interim dividend 2 075p 1 875p per share 4 503 cent 4 24 cent per equiti unit background page 22